VeruVERU
VERU
About: Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Employees: 210
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
62% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 29
6% more funds holding
Funds holding: 122 [Q4 2024] → 129 (+7) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
7.02% less ownership
Funds ownership: 39.38% [Q4 2024] → 32.35% (-7.02%) [Q1 2025]
38% less capital invested
Capital invested by funds: $37.5M [Q4 2024] → $23.2M (-$14.3M) [Q1 2025]
86% less call options, than puts
Call options by funds: $255K | Put options by funds: $1.77M
Research analyst outlook
We haven’t received any recent analyst ratings for VERU.
Financial journalist opinion
Based on 4 articles about VERU published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Veru to Participate in the Virtual BTIG Obesity Health Forum
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the company will be participating in one-on-one meetings and a fire side chat presentation with investors at the virtual BTIG Obesity Health Forum on June 18, 2025.
Positive
Benzinga
2 weeks ago
Veru's Enobosarm Shows Muscle In Wegovy Combo Trial
Penny stock Veru Inc. VERU on Wednesday released topline safety results from the Phase 2b QUALITY study of enobosarm 3mg, enobosarm 6mg, or placebo to enhance fat loss and prevent muscle loss in patients over 60 years receiving Novo Nordisk A/S' NVO Wegovy (semaglutide) for chronic weight management.
Neutral
GlobeNewsWire
2 weeks ago
Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3mg will advance as the proposed oral dose for the Phase 3 clinical program-- -- Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects (Diarrhea, Nausea, and GERD) compared to semaglutide alone--
Positive
Seeking Alpha
2 weeks ago
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces lean mass loss by 99%, preserves physical function, and enhances selective fat loss when combined with semaglutide (Wegovy). VERU's lean balance sheet, with $20 million in cash and no debt, positions it favorably to take advantage of near-term catalysts.
Neutral
Seeking Alpha
1 month ago
Veru Inc. (VERU) Q2 2025 Earnings Call Transcript
Veru Inc. (NASDAQ:VERU ) Q2 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner - Chairman, President and Chief Executive Officer Michele Greco - Chief Financial Officer and Chief Administrative Officer Gary Barnette - Chief Scientific Officer Conference Call Participants Anthea Li - Jefferies Gary Nachman - Raymond James William Wood - B. Riley Securities Leland Gershell - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to Veru Inc.'s Investor Conference Call.
Neutral
Accesswire
1 month ago
JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level
Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D.
Neutral
GlobeNewsWire
1 month ago
Veru Participates in a Virtual Investor KOL Connect Segment
-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the release of a Virtual Investor KOL segment featuring Louis J. Aronne, MD, FACP.
Neutral
GlobeNewsWire
1 month ago
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 --
Neutral
GlobeNewsWire
1 month ago
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Thursday, May 8, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 second quarter financial results and to provide a business update.
Neutral
GlobeNewsWire
1 month ago
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the Company will present at the 2nd Annual GLP-1-Based Therapeutics Summit, taking place April 29 - May 1, 2025, in Boston, Massachusetts.
Charts implemented using Lightweight Charts™